Hyaluronic acid for anticancer drug and nucleic acid delivery

Advanced Drug Delivery Reviews

Volumn 97, Issue , 2016, Pages 204-236

  Dosio, Franco ^a   Arpicco, Silvia ^a   Stella, Barbara ^a   Fattal, Elias ^b,c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c CNRS   (France)

Author keywords

Anticancer agents; CD44; Conjugates; Drug delivery systems; Hyaluronic acid; Nanotechnology

Indexed keywords

BIOCOMPATIBILITY; CONTROLLED DRUG DELIVERY; LIPOSOMES; NANOTECHNOLOGY; NUCLEIC ACIDS; ORGANIC ACIDS; TARGETED DRUG DELIVERY;

ANTI-CANCER AGENTS; ANTI-CANCER DRUG DELIVERY; CD44; CONJUGATES; DRUG DELIVERY SYSTEM; INORGANIC NANOSTRUCTURES; LIGAND-RECEPTOR INTERACTIONS; NUCLEIC ACID DELIVERIES;

HYALURONIC ACID;

ANTINEOPLASTIC AGENT; BUTYRIC ACID; CAMPTOTHECIN; CHITOSAN NANOPARTICLE; CISPLATIN; DOXORUBICIN; DRUG CARRIER; FIRTECAN; GOLD NANOPARTICLE; HERMES ANTIGEN; HYALURONIC ACID; LIGAND; LIPOSOME; MACROGOL; MITOXANTRONE; NANOMATERIAL; NANOPARTICLE; NUCLEIC ACID; OLIGOSACCHARIDE; OVALBUMIN; OXALIPLATIN; PACLITAXEL; QUANTUM DOT; QUERCETIN; RETINOIC ACID; EXCIPIENT; HYDROGEL;

BLADDER CANCER; BRAIN METASTASIS; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYDROGEL; LEUKEMIA; LEWIS CARCINOMA; LIVER CELL CARCINOMA; MELANOMA; MICELLE; MOUSE; MYELOMA; NONHUMAN; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; REVIEW; SARCOMA; TUMOR CELL; TUMOR INVASION; VISCOELASTICITY; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; EXCIPIENTS; HUMANS; HYALURONIC ACID; HYDROGELS; NANOSTRUCTURES; NUCLEIC ACIDS;

EID: 84957823779     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.11.011     Document Type: Review

References (319)

1. Reed R.K., Lilja K., Laurent T.C. Hyaluronan in the rat with special reference to the skin. Acta Physiol. Scand. 1988, 134:405-411.
2. Schaefer L., Schaefer R.M. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res. 2010, 339:237-246.
3. Toole B.P. Hyaluronan in morphogenesis. Semin. Cell Dev. Biol. 2001, 12:79-87.
4. Stern R., Asari A.A., Sugahara K.N. Hyaluronan fragments: An information-rich system. Eur. J. Cell Biol. 2006, 85:699-715.
5. Jiang D., Liang J., Noble P.W. Hyaluronan in tissue injury and repair. Annu. Rev. Cell Dev. Biol. 2007, 435-461.
6. Neuman M.G., Nanau R.M., Oruna-Sanchez L., Coto G. Hyaluronic Acid and Wound Healing. J. Pharm. Pharm. Sci. 2015, 18:53-60.
7. Sironen R.K., Tammi M., Tammi R., Auvinen P.K., Anttila M., Kosma V.M. Hyaluronan in human malignancies. Exp. Cell Res. 2011, 317:383-391.
8. Turley E.A., Noble P.W., Bourguignon L.Y.W. Signaling properties of hyaluronan receptors. J. Biol. Chem. 2002, 277:4589-4592.
9. Volpi N., Schiller J., Stern R., Šoltés L. Role, metabolism, chemical modifications and applications of hyaluronan. Curr. Med. Chem. 2009, 16:1718-1745.
10. Stern R. Association between cancer and "acid mucopolysaccharides": An old concept comes of age, finally. Semin. Cancer Biol. 2008, 18:238-243.
11. Itano N., Sawai T., Yoshida M., Lenas P., Yamada Y., Imagawa M., Shinomura T., Hamaguchi M., Yoshida Y., Ohnuki Y., Miyauchi S., Spicer A.P., McDonald J.A., Kimata K. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J. Biol. Chem. 1999, 274:25085-25092.
12. Vigetti D., Viola M., Karousou E., De Luca G., Passi A. Metabolic control of hyaluronan synthases. Matrix Biol. 2014, 35:8-13.
13. Weigel P.H., Hascall V.C., Tammi M. Hyaluronan synthases. J. Biol. Chem. 1997, 272:13997-14000.
14. Fraser J.R.E., Appelgren L.E., Laurent T.C. Tissue uptake of circulating hyaluronic acid - A whole body autoradiographic study. Cell Tissue Res. 1983, 233:285-293.
15. Laurent T.C. The chemistry, biology and medical applications of hyaluronan and its derivatives 1998, Portland Press, London.
16. Laurent T.C., Fraser J.R.E. Hyaluronan. FASEB J. 1992, 6:2397-2404.
17. Underhill C. CD44: The hyaluronan receptor. J. Cell Sci. 1992, 103:293-298.
18. Sneath R.J.S., Mangham D.C. The normal structure and function of CD44 and its role in neoplasia. J. Clin. Pathol. 1998, 51:191-200.
19. Goodfellow P.N., Banting G., Wiles M.V., Tunnacliffe A., Parkar M., Solomon E., Dalchau R., Fabre J.W. The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur. J. Immunol. 1982, 12:659-663.
20. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur. J. Cancer 2010, 46:1271-1277.
21. Naor D., Nedvetzki S., Golan I., Melnik L., Faitelson Y. CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 2002, 39:527-579.
22. Cichy J., Puré E. The liberation of CD44. J. Cell Biol. 2003, 161:839-843.
23. Naor D., Wallach-Dayan S.B., Zahalka M.A., Sionov R.V. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin. Cancer Biol. 2008, 18:260-267.
24. Misra S., Heldin P., Hascall V.C., Karamanos N.K., Skandalis S.S., Markwald R.R., Ghatak S. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011, 278:1429-1443.
25. Günthert U., Hofmann M., Rudy W., Reber S., Zöller M., Haußmann I., Matzku S., Wenzel A., Ponta H., Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65:13-24.
26. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat. Rev. Cancer 2011, 11:254-267.
27. Jaggupilli A., Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: An enduring ambiguity. Clin. Dev. Immunol. 2012, 2012.
28. Maxwell C.A., McCarthy J., Turley E. Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual oncogenic functions?. J. Cell Sci. 2008, 121:925-932.
29. Yang B., Yang B.L., Savani R.C., Turley E.A. Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. EMBO J. 1994, 13:286-296.
30. Telmer P.G., Tolg C., McCarthy J.B., Turley E.A. How does a protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression?. Commun. Integr. Biol. 2011, 4:182-185.
31. Gust K.M., Hofer M.D., Perner S.R., Kim R., Chinnaiyan A.M., Varambally S., Moller P., Rinnab L., Rubin M.A., Greiner J., Schmitt M., Kuefer R., Ringhoffer M. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia 2009, 11:956-963.
32. Shigeishi H., Fujimoto S., Hiraoka M., Ono S., Taki M., Ohta K., Higashikawa K., Kamata N. Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-associated protein in human oral squamous cell carcinomas. Int. J. Oncol. 2009, 34:1565-1571.
33. Jiang D., Liang J., Noble P.W. Hyaluronan as an immune regulator in human diseases. Physiol. Rev. 2011, 91:221-264.
34. Itano N., Kimata K. Altered hyaluronan biosynthesis in cancer progression. Semin. Cancer Biol. 2008, 18:268-274.
35. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 2004, 4:528-539.
36. Wu M., Cao M., He Y., Liu Y., Yang C., Du Y., Wang W., Gao F. A novel role of low molecular weight hyaluronan in breast cancer metastasis. FASEB J. 2015, 29:1290-1298.
37. West D.C., Hampson I.N., Arnold F., Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985, 228:1324-1336.
38. Misra S., Ghatak S., Toole B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem. 2005, 280:20310-20315.
39. Liu D., Pearlman E., Diaconu E., Guo K., Mori H., Haqqi T., Markowitz S., Willson J., Sy M.S. Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc. Natl. Acad. Sci. 1996, 93:7832-7837.
40. Jiang D., Liang J., Fan J., Yu S., Chen S., Luo Y., Prestwich G.D., Mascarenhas M.M., Garg H.G., Quinn D.A., Homer R.J., Goldstein D.R., Bucala R., Lee P.J., Medzhitov R., Noble P.W. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 2005, 11:1173-1179.
41. Hosono K., Nishida Y., Knudson W., Knudson C.B., Naruse T., Suzuki Y., Ishiguro N. Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am. J. Pathol. 2007, 171:274-286.
42. Skandalis S.S., Gialeli C., Theocharis A.D., Karamanos N.K. Chapter Eleven - Advances and advantages of nanomedicine in the pharmacological targeting of hyaluronan-CD44 interactions and signaling in cancer. Adv. Cancer Res. 2014, 277-317. Academic Press. A.S. Melanie, H. Paraskevi (Eds.).
43. Liu L., Liu Y., Li J., Du G., Chen J. Microbial production of hyaluronic acid: current state, challenges, and perspectives. Microb. Cell Factories 2011, 10:99.
44. Liu L., Du G., Chen J., Zhu Y., Wang M., Sun J. Microbial production of low molecular weight hyaluronic acid by adding hydrogen peroxide and ascorbate in batch culture of Streptococcus zooepidemicus. Bioresour. Technol. 2009, 100:362-367.
45. Wu Y. Preparation of low-molecular-weight hyaluronic acid by ozone treatment. Carbohydr. Polym. 2012, 89:709-712.
46. Stern R., Kogan G., Jedrzejas M.J., Šoltés L. The many ways to cleave hyaluronan. Biotechnol. Adv. 2007, 25:537-557.
47. Han X., Li Z., Sun J., Luo C., Li L., Liu Y., Du Y., Qiu S., Ai X., Wu C., Lian H., He Z. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: Probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation. J. Control. Release 2015, 197:29-40.
48. Fang J., Nakamura H., Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63:136-151.
49. Wei X., Senanayake T.H., Warren G., Vinogradov S.V. Hyaluronic Acid-Based Nanogel-Drug Conjugates with Enhanced Anticancer Activity Designed for the Targeting of CD44-Positive and Drug-Resistant Tumors. Bioconjug. Chem. 2013, 24:658-668.
50. Hertweck M.K., Erdfelder F., Kreuzer K.A. CD44 in hematological neoplasias. Ann. Hematol. 2011, 90:493-508.
51. Russo R.I.C., García M.G., Alaniz L., Blanco G., Alvarez E., Hajos S.E. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int. J. Cancer 2008, 122:1012-1018.
52. Xu X., Jha A.K., Harrington D.A., Farach-Carson M.C., Jia X. Hyaluronic acid-based hydrogels: From a natural polysaccharide to complex networks. Soft Matter 2012, 8:3280-3294.
53. Garg H.G., Hales C.A. Chemistry and biology of hyaluronan 2004, Elsevier.
54. Schanté C.E., Zuber G., Herlin C., Vandamme T.F. Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications. Carbohydr. Polym. 2011, 85:469-489.
55. Collins M.N., Birkinshaw C. Hyaluronic acid based scaffolds for tissue engineering-A review. Carbohydr. Polym. 2013, 92:1262-1279.
56. Plattt V.M., Szoka F.C. Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharm. 2008, 5:474-486.
57. Oh E.J., Park K., Kim K.S., Kim J., Yang J.-A., Kong J.-H., Lee M.Y., Hoffman A.S., Hahn S.K. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J. Control. Release 2010, 141:2-12.
58. Pouyani T., Prestwich G.D. Functionalized derivatives of hyaluronic acid oligosaccharides: Drug carriers and novel biomaterials. Bioconjug. Chem. 1994, 5:339-347.
59. Bulpitt P., Aeschlimann D. New strategy for chemical modification of hyaluronic acid: Preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels. J. Biomed. Mater. Res. 1999, 47:152-169.
60. Coradini D., Pellizzaro C., Abolafio G., Bosco M., Scarlata I., Cantoni S., Stucchi L., Zorzet S., Turrin C., Sava G., Perbellini A., Daidone M. Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study. Investig. New Drugs 2004, 22:207-217.
61. Pravata L., Braud C., Boustta M., El Ghzaoui A., Tømmeraas K., Guillaumie F., Schwach-Abdellaoui K., Vert M. New amphiphilic lactic acid oligomer - Hyaluronan conjugates: Synthesis and physicochemical characterization. Biomacromolecules 2008, 9:340-348.
62. Lee H., Lee K., Park T.G. Hyaluronic Acid-Paclitaxel Conjugate Micelles: Synthesis, Characterization, and Antitumor Activity. Bioconjug. Chem. 2008, 19:1319-1325.
63. Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci. Polym. Symp. 1975, 51:135-153.
64. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 2011, 8:2101-2141.
65. Battistini F.D., Olivera M.E., Manzo R.H. Equilibrium and release properties of hyaluronic acid-drug complexes. Eur. J. Pharm. Sci. 2013, 49:588-594.
66. Dosio F., Brusa P., Cattel L. Immunotoxins and anticancer drug conjugate assemblies: The role of the linkage between components. Toxins (Basel) 2011, 3:848-883.
67. Goodarzi N., Varshochian R., Kamalinia G., Atyabi F., Dinarvand R. A review of polysaccharide cytotoxic drug conjugates for cancer therapy. Carbohydr. Polym. 2013, 92:1280-1293.
68. Akima K., Ito H., Iwata Y., Matsuo K., Watari N., Yanagi M., Hagi H., Oshima K., Yagita A., Atomi Y., Tatekawa I. Evaluation of antitumor activities of hyaluronate binding antitumor drugs: Synthesis, characterization and antitumor activity. J. Drug Target. 1996, 4:1-8.
69. Coradini D., Pellizzaro C., Miglierini G., Daidone M.G., Perbellini A. Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the anti-proliferative activity on a breast-cancer cell line. Int. J. Cancer 1999, 81:411-416.
70. Speranza A., Pellizzaro C., Coradini D. Hyaluronic acid butyric esters in cancer therapy. Anti-Cancer Drugs 2005, 16:373-379.
71. Pellizzaro C., Speranza A., Zorzet S., Crucil I., Sava G., Scarlata I., Cantoni S., Fedeli M., Coradini D. Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-but, a hyaluronic butyric ester: A preliminary report. Pancreas 2008, 36:e15-e23.
72. Coradini D., Pellizzaro C., Scarlata I., Zorzet S., Garrovo C., Abolafio G., Speranza A., Fedeli M., Cantoni S., Sava G., Daidone M.G., Perbellini A. A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: Preliminary preclinical results. Leukemia 2006, 20:785-792.
73. Mekhail T.M., Markman M. Paclitaxel in cancer therapy. Expert. Opin. Pharmacother. 2002, 3:755-766.
74. Rosato A., Banzato A., De Luca G., Renier D., Bettella F., Pagano C., Esposito G., Zanovello P., Bassi P. HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol. Oncol. 2006, 24:207-215.
75. Banzato A., Rondina M., Meléndez-Alafort L., Zangoni E., Nadali A., Renier D., Moschini G., Mazzi U., Zanovello P., Rosato A. Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. Nucl. Med. Biol. 2009, 36:525-533.
76. De Stefano I., Battaglia A., Zannoni G.F., Prisco M.G., Fattorossi A., Travaglia D., Baroni S., Renier D., Scambia G., Ferlini C., Gallo D. Hyaluronic acid-paclitaxel: Effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemother. Pharmacol. 2011, 68:107-116.
77. Banzato A., Bobisse S., Rondina M., Renier D., Bettella F., Esposito G., Quintieri L., Melendez-Alafort L., Mazzi U., Zanovello P., Rosato A. A paclitaxel-hyaluronan bioconjugateTargeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res. 2008, 14:3598-3606.
78. Campisi M., Renier D. ONCOFID-P a hyaluronic acid paclitaxel conjugate for the treatment of refractory bladder cancer and peritoneal carcinosis. Curr. Bioact. Compd. 2011, 7:27-32.
79. Montagner I.M., Banzato A., Zuccolotto G., Renier D., Campisi M., Bassi P., Zanovello P., Rosato A. Paclitaxel-hyaluronan hydrosoluble bioconjugate: Mechanism of action in human bladder cancer cell lines. Urol. Oncol. 2013, 31:1261-1269.
80. Bassi P.F., Volpe A., D'Agostino D., Palermo G., Renier D., Franchini S., Rosato A., Racioppi M. Paclitaxel-hyaluronic acid for intravesical therapy of bacillus calmette-gurin refractory carcinoma in situ of the bladder: Results of a phase i study. J. Urol. 2011, 185:445-449.
81. Luo Y., Prestwich G.D. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug. Chem. 1999, 10:755-763.
82. Auzenne E., Ghosh S.C., Khodadadian M., Rivera B., Farquhar D., Price R.E., Ravoori M., Kundra V., Freedman R.S., Klostergaard J. Hyaluronic acid-paclitaxel: Antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 2007, 9:479-486.
83. Lee S.J., Han H.D., Stone R.L., Bottsford-Miller J., Shen D.Y., Lu C., Nishimura M., Zand B., Thanapprapasr D., Jennings N.B., Kang Y., Huang J., Hu W., Sood A.K., Ghosh S.C., Auzenne E.J., Lopez-Araujo A., Klostergaard J., Pecot C.V. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin. Cancer Res. 2012, 18:4114-4121.
84. Galer C.E., Sano D., Ghosh S.C., Hah J.H., Auzenne E., Hamir A.N., Myers J.N., Klostergaard J. Hyaluronic acid-paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism. Oral Oncol. 2011, 47:1039-1047.
85. Xin D., Wang Y., Xiang J. The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: Synthesis, self-assembled property, drug release, and in vitro efficiency. Pharm. Res. 2010, 27:380-389.
86. Mittapalli R.K., Liu X., Adkins C.E., Nounou M.I., Bohn K.A., Terrell T.B., Qhattal H.S., Geldenhuys W.J., Palmieri D., Steeg P.S., Smith Q.R., Lockman P.R. Paclitaxel-hyaluronic nanoConjugates prolong overall survival in a preclinical brain metastases of breast cancer model. Mol. Cancer Ther. 2013, 12:2389-2399.
87. Pizzolato J.F., Saltz L.B. The camptothecins. Lancet 2003, 361:2235-2242.
88. Serafino A., Zonfrillo M., Andreola F., Psaila R., Mercuri L., Moroni N., Renier D., Campisi M., Secchieri C., Pierimarchi P. CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. Curr. Cancer Drug Targets 2011, 11:572-585.
89. Tringali G., Bettella F., Greco M.C., Campisi M., Renier D., Navarra P. Pharmacokinetic profile of Oncofid-S after intraperitoneal and intravenous administration in the rat. J. Pharm. Pharmacol. 2012, 64:360-365.
90. Montagner I.M., Merlo A., Zuccolotto G., Renier D., Campisi M., Pasut G., Zanovello P., Rosato A. Peritoneal tumor carcinomatosis: Pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs. PLoS One 2014, 9.
91. Xu Z., Zheng W., Yin Z. Synthesis and optimization of a bifunctional hyaluronan-based camptothecin prodrug. Arch. Pharm. 2014, 347:240-246.
92. Yang X., Dogan I., Pannala V.R., Kootala S., Hilborn J., Ossipov D. A hyaluronic acid-camptothecin nanoprodrug with cytosolic mode of activation for targeting cancer. Polym. Chem. 2013, 4:4621-4630.
93. Takemura G., Fujiwara H. Doxorubicin-Induced Cardiomyopathy. From the Cardiotoxic Mechanisms to Management. Prog. Cardiovasc. Dis. 2007, 49:330-352.
94. Cai S., Thati S., Bagby T.R., Diab H.M., Davies N.M., Cohen M.S., Forrest M.L., Laird M. Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. J. Control. Release 2010, 146:212-218.
95. Oommen O.P., Garousi J., Sloff M., Varghese O.P. Tailored doxorubicin-hyaluronan conjugate as a potent anticancer glyco-drug: An alternative to prodrug approach. Macromol. Biosci. 2014, 14:327-333.
96. Chhikara B.S., Mandal D., Parang K. Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate. J. Med. Chem. 2012, 55:1500-1510.
97. Chhikara B.S., Jean N.St., Mandal D., Kumar A., Parang K. Fatty acyl amide derivatives of doxorubicin: Synthesis and in vitro anticancer activities. Eur. J. Med. Chem. 2011, 46:2037-2042.
98. Kratz F. INNO-206 (DOXO-EMCH), an albumin-binding prodrug of doxorubicin under development for Phase II studies. Curr. Bioact. Compd. 2011, 7:33-38.
99. Dubowchik G.M., Radia S., Mastalerz H., Walker M.A., Firestone R.A., Dalton King H., Hofstead S.J., Willner D., Lasch S.J., Trail P.A. Doxorubicin immunoconjugates containing bivalent, lysosomally-Cleavable dipeptide linkages. Bioorg. Med. Chem. Lett. 2002, 12:1529-1532.
100. Fu C., Li H., Li N., Miao X., Xie M., Du W., Zhang L.-M. Conjugating an anticancer drug onto thiolated hyaluronic acid by acid liable hydrazone linkage for its gelation and dual stimuli-response release. Carbohydr. Polym. 2015, 128:163-170.
101. Camacho K.M., Kumar S., Menegatti S., Vogus D.R., Anselmo A.C., Mitragotri S. Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid. J. Control. Release 2015, 210:198-207.
102. Desoize B., Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit. Rev. Oncol. Hematol. 2002, 42:317-325.
103. Cai S., Xie Y., Bagby T.R., Forrest M.L., Cohen M.S. Intralymphatic Chemotherapy Using a Hyaluronan-Cisplatin Conjugate. J. Surg. Res. 2008, 147:247-252.
104. Xie Y., Aillon K.L., Cai S., Christian J.M., Davies N.M., Berkland C.J., Forrest M.L. Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int. J. Pharm. 2010, 392:156-163.
105. Quan Y.H., Kim B., Park J.H., Choi Y., Choi Y.H., Kim H.K. Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44. Exp. Lung Res. 2014, 40:475-484.
106. Cohen S.M., Rockefeller N., Mukerji R., Durham D., Forrest M.L., Cai S., Cohen M.S., Shnayder Y. Efficacy and toxicity of peritumoral delivery of nanoconjugated cisplatin in an in vivo murine model of head and neck squamous cell carcinoma. JAMA Otolaryngol. Head Neck Surg. 2013, 139:382-387.
107. Yang Q., Aires D.J., Cai S., Fraga G.R., Zhang D., Li C.Z., Laird Forrest M. In vivo efficacy of nano hyaluronan-conjugated cisplatin for treatment of murine melanoma. J. Drugs Dermatol. 2014, 13:283-287.
108. Venable R.O., Worley D.R., Gustafson D.L., Hansen R.J., Ehrhart E.J., Cai S., Cohen M.S., Laird Forrest M. Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas. Am. J. Vet. Res. 2012, 73:1969-1973.
109. Cai S., Alhowyan A.A.B., Yang Q., Forrest W.C.M., Shnayder Y., Forrest M.L. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates. J. Drug Target. 2014, 22:648-657.
110. Cohen S.M., Mukerji R., Cai S., Damjanov I., Forrest M.L., Cohen M.S. Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo. Am. J. Surg. 2011, 202:646-653.
111. Ling X., Shen Y., Sun R., Zhang M., Li C., Mao J., Xing J., Sun C., Tu J. Tumor-targeting delivery of hyaluronic acid-platinum(iv) nanoconjugate to reduce toxicity and improve survival. Polym. Chem. 2015, 6:1541-1552.
112. Ferguson E.L., Alshame A.M.J., Thomas D.W. Evaluation of hyaluronic acid-protein conjugates for polymer masked-unmasked protein therapy. Int. J. Pharm. 2010, 402:95-102.
113. Lee Y.H., Yoon H.Y., Shin J.M., Saravanakumar G., Noh K.H., Song K.H., Jeon J.H., Kim D.W., Lee K.M., Kim K., Kwon I.C., Park J.H., Kim T.W. A polymeric conjugate foreignizing tumor cells for targeted immunotherapy in vivo. J. Control. Release 2015, 199:98-105.
114. Pang X., Lu Z., Du H., Yang X., Zhai G. Hyaluronic acid-quercetin conjugate micelles: synthesis, characterization, in vitro and in vivo evaluation. Colloids Surf. B: Biointerfaces 2014, 123:778-786.
115. Liu Y., Sun J., Zhang P., He Z. Amphiphilic polysaccharide-hydrophobicized graft polymeric micelles for drug delivery nanosystems. Curr. Med. Chem. 2011, 18:2638-2648.
116. Tian Y., Mao S. Amphiphilic polymeric micelles as the nanocarrier for peroral delivery of poorly soluble anticancer drugs. Expert Opin. Drug Deliv. 2012, 9:687-700.
117. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 2010, 188:759-768.
118. Qiu L., Li Z., Qiao M., Long M., Wang M., Zhang X., Tian C., Chen D. Self-assembled pH-responsive hyaluronic acid-g-poly((L)-histidine) copolymer micelles for targeted intracellular delivery of doxorubicin. Acta Biomater. 2014, 10:2024-2035.
119. Qiu L., Qiao M., Chen Q., Tian C., Long M., Wang M., Li Z., Hu W., Li G., Cheng L., Cheng L., Hu H., Zhao X., Chen D. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin. Biomaterials 2014, 35:9877-9887.
120. Li J., Huo M., Wang J., Zhou J., Mohammad J.M., Zhang Y., Zhu Q., Waddad A.Y., Zhang Q. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 2012, 33:2310-2320.
121. Li J., Yin T., Wang L., Yin L., Zhou J., Huo M. Biological evaluation of redox-sensitive micelles based on hyaluronic acid-deoxycholic acid conjugates for tumor-specific delivery of paclitaxel. Int. J. Pharm. 2015, 483:38-48.
122. Yin T., Wang L., Yin L., Zhou J., Huo M. Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer. Biomaterials 2015, 61:10-25.
123. Shen Y., Wang B., Lu Y., Ouahab A., Li Q., Tu J. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery. Int. J. Pharm. 2011, 414:233-243.
124. Hu Y., Xie J., Tong Y.W., Wang C.H. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J. Control. Release 2007, 118:7-17.
125. Smejkalova D., Nesporova K., Hermannova M., Huerta-Angeles G., Cozikova D., Vistejnova L., Safrankova B., Novotny J., Kucerik J., Velebny V. Paclitaxel isomerisation in polymeric micelles based on hydrophobized hyaluronic acid. Int. J. Pharm. 2014, 466:147-155.
126. Saadat E., Amini M., Khoshayand M.R., Dinarvand R., Dorkoosh F.A. Synthesis and optimization of a novel polymeric micelle based on hyaluronic acid and phospholipids for delivery of paclitaxel, in vitro and in-vivo evaluation. Int. J. Pharm. 2014, 475:163-173.
127. Thomas R.G., Moon M., Lee S., Jeong Y.Y. Paclitaxel loaded hyaluronic acid nanoparticles for targeted cancer therapy: In vitro and in vivo analysis. Int. J. Biol. Macromol. 2014, 72:510-518.
128. Liu X., Zheng J., Xu J., Bai H., Yi C., Jiang J., Mi W. Method for preparing coumarin-grafted hyaluronic acid micelle emulsifier 2012, (CN102344501A).
129. Liu Y., Sun J., Cao W., Yang J., Lian H., Li X., Sun Y., Wang Y., Wang S., He Z. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int. J. Pharm. 2011, 421:160-169.
130. Liu Y., Sun J., Lian H., Cao W., Wang Y., He Z. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution. J. Pharm. Sci. 2014, 103:1538-1547.
131. Liu Y., Sun J., Lian H., Li X., Cao W., Bai L., Wang Y., He Z. Determination of paclitaxel in hyaluronic acid polymeric micelles in rat blood by protein precipitation-micelle breaking method: application to a pharmacokinetic study. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2013, 935:10-15.
132. Lee H., Ahn C.H., Park T.G. Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin. Macromol. Biosci. 2009, 9:336-342.
133. Son G.M., Kim H.Y., Ryu J.H., Chu C.W., Kang D.H., Park S.B., Jeong Y.I. Self-assembled polymeric micelles based on hyaluronic acid-g-poly(D, L-lactide-co-glycolide) copolymer for tumor targeting. Int. J. Mol. Sci. 2014, 15:16057-16068.
134. Pitarresi G., Palumbo F.S., Albanese A., Fiorica C., Picone P., Giammona G. Self-assembled amphiphilic hyaluronic acid graft copolymers for targeted release of antitumoral drug. J. Drug Target. 2010, 18:264-276.
135. Yim H., Park W., Kim D., Fahmy T.M., Na K. A self-assembled polymeric micellar immunomodulator for cancer treatment based on cationic amphiphilic polymers. Biomaterials 2014, 35:9912-9919.
136. Li K., Liu H., Gao W., Chen M., Zeng Y., Liu J., Xu L., Wu D. Mulberry-like dual-drug complicated nanocarriers assembled with apogossypolone amphiphilic starch micelles and doxorubicin hyaluronic acid nanoparticles for tumor combination and targeted therapy. Biomaterials 2015, 39:131-144.
137. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54:987-992.
138. Barenholz Y. Doxil® - The first FDA-approved nano-drug: Lessons learned. J. Control. Release 2012, 160:117-134.
139. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 2006, 1:297-315.
140. Allen T.M., Cullis P.R. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65:36-48.
141. Deshpande P.P., Biswas S., Torchilin V.P. Current trends in the use of liposomes for tumor targeting. Nanomedicine 2013, 8:1509-1528.
142. Ozpolat B., Sood A.K., Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv. Drug Deliv. Rev. 2014, 66:110-116.
143. Yerushalmi N., Margalit R. Hyaluronic acid-modified bioadhesive liposomes as local drug depots: effects of cellular and fluid dynamics on liposome retention at target sites. Arch. Biochem. Biophys. 1998, 349:21-26.
144. Kim E., Yang J., Park J., Kim S., Kim N.H., Yook J.I., Suh J.S., Haam S., Huh Y.M. Consecutive Targetable Smart Nanoprobe for Molecular Recognition of Cytoplasmic microRNA in Metastatic Breast Cancer. ACS Nano 2012, 6:8525-8535.
145. Qhattal H.S.S., Liu X. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol. Pharm. 2011, 8:1233-1246.
146. Qhattal H.S.S., Hye T., Alali A., Liu X. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano 2014, 8:5423-5440.
147. Arpicco S., De Rosa G., Fattal E. Lipid-Based Nanovectors for Targeting of CD44-Overexpressing Tumor Cells. J. Drug Deliv. 2013, 2013:8.
148. Mizrahy S., Raz S.R., Hasgaard M., Liu H., Soffer-Tsur N., Cohen K., Dvash R., Landsman-Milo D., Bremer M.G.E.G., Moghimi S.M., Peer D. Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J. Control. Release 2011, 156:231-238.
149. Glucksam-Galnoy Y., Zor T., Margalit R. Hyaluronan-modified and regular multilamellar liposomes provide sub-cellular targeting to macrophages, without eliciting a pro-inflammatory response. J. Control. Release 2012, 160:388-393.
150. Landesman-Milo D., Goldsmith M., Leviatan Ben-Arye S., Witenberg B., Brown E., Leibovitch S., Azriel S., Tabak S., Morad V., Peer D. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett. 2013, 334:221-227.
151. Gan L., Wang J., Zhao Y., Chen D., Zhu C., Liu J., Gan Y. Hyaluronan-modified core-shell liponanoparticles targeting CD44-positive retinal pigment epithelium cells via intravitreal injection. Biomaterials 2013, 34:5978-5987.
152. Lesley J., Hascall V.C., Tammi M., Hyman R. Hyaluronan binding by cell surface CD44. J. Biol. Chem. 2000, 275:26967-26975.
153. Eliaz R.E., Szoka F.C. Liposome-encapsulated doxorubicin targeted to CD44: A strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001, 61:2592-2601.
154. Dalla Pozza E., Lerda C., Costanzo C., Donadelli M., Dando I., Zoratti E., Scupoli M.T., Beghelli S., Scarpa A., Fattal E., Arpicco S., Palmieri M. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Biochim. Biophys. Acta 2013, 1828:1396-1404.
155. Ruhela D., Kivimäe S., Szoka F.C. Chemoenzymatic Synthesis of Oligohyaluronan-Lipid Conjugates. Bioconjug. Chem. 2014, 25:718-723.
156. Surace C., Arpicco S., Dufay-Wojcicki A., Marsaud V., Bouclier C., Clay D., Cattel L., Renoir J.M., Fattal E. Lipoplexes Targeting the CD44 Hyaluronic Acid Receptor for Efficient Transfection of Breast Cancer Cells. Mol. Pharm. 2009, 6:1062-1073.
157. Wojcicki A.D., Hillaireau H., Nascimento T.L., Arpicco S., Taverna M., Ribes S., Bourge M., Nicolas V., Bochot A., Vauthier C. Hyaluronic acid-bearing lipoplexes: Physico-chemical characterization and in vitro targeting of the CD44 receptor. J. Control. Release 2012, 162:545-552.
158. Park J.H., Cho H.J., Yoon H.Y., Yoon I.S., Ko S.H., Shim J.S., Cho J.H., Park J.H., Kim K., Kwon I.C., Kim D.D. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. J. Control. Release 2014, 174:98-108.
159. Arpicco S., Lerda C., Dalla Pozza E., Costanzo C., Tsapis N., Stella B., Donadelli M., Dando I., Fattal E., Cattel L., Palmieri M. Hyaluronic acid-coated liposomes for active targeting of gemcitabine. Eur. J. Pharm. Biopharm. 2013, 85:373-380.
160. Toriyabe N., Hayashi Y., Hyodo M., Harashima H. Synthesis and Evaluation of Stearylated Hyaluronic Acid for the Active Delivery of Liposomes to Liver Endothelial Cells. Biol. Pharm. Bull. 2011, 34:1084-1089.
161. Peer D., Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. J. Cancer 2004, 108:780-789.
162. Peer D., Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 2004, 6:343-353.
163. Jiang T., Zhang Z., Zhang Y., Lv H., Zhou J., Li C., Hou L., Zhang Q. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012, 33:9246-9258.
164. Li L., Heldin C.-H., Heldin P. Inhibition of platelet-derived growth factor-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44. J. Biol. Chem. 2006, 281:26512-26519.
165. Cohen Z.R., Ramishetti S., Peshes-Yaloz N., Goldsmith M., Wohl A., Zibly Z., Peer D. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano 2015, 9:1581-1591.
166. Simons K., Gerl M.J. Revitalizing membrane rafts: new tools and insights. Nat. Rev. Mol. Cell Biol. 2010, 11:688-699.
167. Hooper N.M. Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae (review). Mol. Membr. Biol. 1999, 16:145-156.
168. Ponta H., Sherman L., Herrlich P.A. CD44: From adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 2003, 4:33-45.
169. Long M., Huang S.-H., Wu C.-H., Shackleford G.M., Jong A. Lipid raft/caveolae signaling is required for Cryptococcus neoformans invasion into human brain microvascular endothelial cells. J. Biomed. Sci. 2012, 19.
170. Wrobel T., Dziegiel P., Mazur G., Zabel M., Kuliczkowski K., Szuba A. LYVE-1 expression on high endothelial venules (HEVs) of lymph nodes. Lymphology 2005, 38:107-110.
171. Harris E.N., Kyosseva S.V., Weigel J.A., Weigel P.H. Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE). J. Biol. Chem. 2007, 282:2785-2797.
172. Ossipov D.A. Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert Opin. Drug Deliv. 2010, 7:681-703.
173. Zhong Y., Meng F., Deng C., Zhong Z. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules 2014, 15:1955-1969.
174. Soula O., Charvet R. Nanoparticles comprising a hyaluronic acid-polylactide diblock copolymer 2015, (WO2015097242A1).
175. Jeong Y.I., Kim Do H., Chung C.W., Yoo J.J., Choi K.H., Kim C.H., Ha S.H., Kang D.H. Self-assembled nanoparticles of hyaluronic acid/poly(DL-lactide-co-glycolide) block copolymer. Colloids Surf. B: Biointerfaces 2012, 90:28-35.
176. Huang J., Zhang H., Yu Y., Chen Y., Wang D., Zhang G., Zhou G., Liu J., Sun Z., Sun D., Lu Y., Zhong Y. Biodegradable self-assembled nanoparticles of poly (D, L-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer. Biomaterials 2014, 35:550-566.
177. Yadav A.K., Mishra P., Mishra A.K., Jain S., Agrawal G.P. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine 2007, 3:246-257.
178. Yadav A.K., Mishra P., Jain S., Mishra A.K., Agrawal G.P. Preparation and characterization of HA-PEG-PCL intelligent core corona nanoparticles for delivery of doxorubicin. J. Drug Target. 2008, 16:464-478.
179. Yadav A.K., Agarwal A., Rai G., Mishra P., Jain S., Mishra A.K., Agrawal H., Agrawal G.P. Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil. Drug Deliv. 2010, 17:561-572.
180. Nair H.B., Huffman S., Veerapaneni P., Kirma N.B., Binkley P., Perla R.P., Evans D.B., Tekmal R.R. Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice. J. Nanosci. Nanotechnol. 2011, 11:3789-3799.
181. Park H.K., Lee S.J., Oh J.S., Lee S.G., Jeong Y.I., Lee H.C. Smart Nanoparticles Based on Hyaluronic Acid for Redox-Responsive and CD44 Receptor-Mediated Targeting of Tumor. Nanoscale Res. Lett. 2015, 10:981.
182. Hu K., Zhou H., Liu Y., Liu Z., Liu J., Tang J., Li J., Zhang J., Sheng W., Zhao Y., Wu Y., Chen C. Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells. Nanoscale 2015, 7:8607-8618.
183. Han H.S., Thambi T., Choi K.Y., Son S., Ko H., Lee M.C., Jo D.G., Chae Y.S., Kang Y.M., Lee J.Y., Park J.H. Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery. Biomacromolecules 2015, 16:447-456.
184. Youm I., Agrahari V., Murowchick J.B., Youan B.B. Uptake and cytotoxicity of docetaxel-loaded hyaluronic acid-grafted oily core nanocapsules in MDA-MB 231 cancer cells. Pharm. Res. 2014, 31:2439-2452.
185. Vangara K.K., Liu J.L., Palakurthi S. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer. Anticancer Res. 2013, 33:2425-2434.
186. Zafar S., Negi L.M., Verma A.K., Kumar V., Tyagi A., Singh P., Iqbal Z., Talegaonkar S. Sterically stabilized polymeric nanoparticles with a combinatorial approach for multi drug resistant cancer: in vitro and in vivo investigations. Int. J. Pharm. 2014, 477:454-468.
187. He M., Zhao Z., Yin L., Tang C., Yin C. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers. Int. J. Pharm. 2009, 373:165-173.
188. Abbad S., Wang C., Waddad A.Y., Lv H., Zhou J. Preparation, in vitro and in vivo evaluation of polymeric nanoparticles based on hyaluronic acid-poly(butyl cyanoacrylate) and D-alpha-tocopheryl polyethylene glycol 1000 succinate for tumor-targeted delivery of morin hydrate. Int. J. Nanomedicine 2015, 10:305-320.
189. Lee C.S., Na K. Photochemically triggered cytosolic drug delivery using pH-responsive hyaluronic acid nanoparticles for light-induced cancer therapy. Biomacromolecules 2014, 15:4228-4238.
190. Wang W., Xi M., Duan X., Wang Y., Kong F.E. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: Synergistic antitumor effect in vitro and in vivo. Int. J. Nanomedicine 2015, 10:3737-3750.
191. Battaglia L., Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin. Drug Deliv. 2012, 9:497-508.
192. Cho H.J., Yoon H.Y., Koo H., Ko S.H., Shim J.S., Lee J.H., Kim K., Kwon I.C., Kim D.D. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic (R) for tumor-targeted delivery of docetaxel. Biomaterials 2011, 32:7181-7190.
193. Jin Y.J., Termsarasab U., Ko S.H., Shim J.S., Chong S., Chung S.J., Shim C.K., Cho H.J., Kim D.D. Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma. Pharm. Res. 2012, 29:3443-3454.
194. Cho H.J., Yoon I.S., Yoon H.Y., Koo H., Jin Y.J., Ko S.H., Shim J.S., Kim K., Kwon I.C., Kim D.D. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials 2012, 33:1190-1200.
195. Park J.H., Lee J.Y., Termsarasab U., Yoon I.S., Ko S.H., Shim J.S., Cho H.J., Kim D.D. Development of poly(lactic-co-glycolic) acid nanoparticles-embedded hyaluronic acid-ceramide-based nanostructure for tumor-targeted drug delivery. Int. J. Pharm. 2014, 473:426-433.
196. Lee J.Y., Yang H., Yoon I.S., Kim S.B., Ko S.H., Shim J.S., Sung S.H., Cho H.J., Kim D.D. Nanocomplexes based on amphiphilic hyaluronic acid derivative and polyethylene glycol-lipid for ginsenoside rg3 delivery. J. Pharm. Sci. 2014, 103:3254-3262.
197. Choi K.Y., Yoon H.Y., Kim J.-H., Bae S.M., Park R.-W., Kang Y.M., Kim I.-S., Kwon I.C., Choi K., Jeong S.Y., Kim K., Park J.H. Smart Nanocarrier Based on PEGylated Hyaluronic Acid for Cancer Therapy. ACS Nano 2011, 5:8591-8599.
198. Yoon H.Y., Koo H., Choi K.Y., Lee S.J., Kim K., Kwon I.C., Leary J.F., Park K., Yuk S.H., Park J.H., Choi K. Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials 2012, 33:3980-3989.
199. Choi K.Y., Jeon E.J., Yoon H.Y., Lee B.S., Na J.H., Min K.H., Kim S.Y., Myung S.J., Lee S., Chen X., Kwon I.C., Choi K., Jeong S.Y., Kim K., Park J.H. Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials 2012, 33:6186-6193.
200. Liu G., Choi K.Y., Bhirde A., Swierczewska M., Yin J., Lee S.W., Park J.H., Hong J.I., Xie J., Niu G., Kiesewetter D.O., Lee S., Chen X. Sticky nanoparticles: a platform for siRNA delivery by a bis(zinc(II) dipicolylamine)-functionalized, self-assembled nanoconjugate. Angew. Chem. Int. Ed. Engl. 2012, 51:445-449.
201. Yoon H.Y., Koo H., Choi K.Y., Chan Kwon I., Choi K., Park J.H., Kim K. Photo-crosslinked hyaluronic acid nanoparticles with improved stability for invivo tumor-targeted drug delivery. Biomaterials 2013, 34:5273-5280.
202. Han H.S., Lee J., Kim H.R., Chae S.Y., Kim M., Saravanakumar G., Yoon H.Y., You D.G., Ko H., Kim K., Kwon I.C., Park J.C., Park J.H. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo. J. Control. Release 2013, 168:105-114.
203. Zhong Y., Zhang J., Cheng R., Deng C., Meng F., Xie F., Zhong Z. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. J. Control. Release 2015, 205:144-154.
204. Yao J., Zhang L., Zhou J., Liu H., Zhang Q. Efficient simultaneous tumor targeting delivery of all-trans retinoid acid and paclitaxel based on hyaluronic acid-based multifunctional nanocarrier. Mol. Pharm. 2013, 10:1080-1091.
205. Yao J., Li Y., Sun X., Dahmani F.Z., Liu H., Zhou J. Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid. Int. J. Nanomedicine 2014, 9:3313-3324.
206. Liang D., Wang A.T., Yang Z.Z., Liu Y.J., Qi X.R. Enhance cancer cell recognition and overcome drug resistance using hyaluronic acid and α-tocopheryl succinate based multifunctional nanoparticles. Mol. Pharm. 2015, 12:2189-2202.
207. Zhang L., Yao J., Zhou J., Wang T., Zhang Q. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs. Int. J. Pharm. 2013, 441:654-664.
208. Mezghrani O., Tang Y., Ke X., Chen Y., Hu D., Tu J., Zhao L., Bourkaib N. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin. Int. J. Pharm. 2015, 478:530-539.
209. Ganesh S., Iyer A.K., Morrissey D.V., Amiji M.M. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 2013, 34:3489-3502.
210. Ganesh S., Iyer A.K., Gattacceca F., Morrissey D.V., Amiji M.M. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J. Control. Release 2013, 172:699-706.
211. Song S., Chen F., Qi H., Li F., Xin T., Xu J., Ye T., Sheng N., Yang X., Pan W. Multifunctional Tumor-Targeting Nanocarriers Based on Hyaluronic Acid-Mediated and pH-Sensitive Properties for Efficient Delivery of Docetaxel. Pharm. Res. 2014, 31:1032-1045.
212. Song S., Qi H., Xu J., Guo P., Chen F., Li F., Yang X., Sheng N., Wu Y., Pan W. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting. Pharm. Res. 2014, 31:2988-3005.
213. Tran T.H., Choi J.Y., Ramasamy T., Truong D.H., Nguyen C.N., Choi H.G., Yong C.S., Kim J.O. Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells. Carbohydr. Polym. 2014, 114:407-415.
214. Shen H., Shi S., Zhang Z., Gong T., Sun X. Coating Solid Lipid Nanoparticles with Hyaluronic Acid Enhances Antitumor Activity against Melanoma Stem-like Cells. Theranostics 2015, 5:755-771.
215. Ramasamy T., Tran T.H., Choi J.Y., Cho H.J., Kim J.H., Yong C.S., Choi H.G., Kim J.O. Layer-by-layer coated lipid-polymer hybrid nanoparticles designed for use in anticancer drug delivery. Carbohydr. Polym. 2014, 102:653-661.
216. Liu D., Liu Z., Wang L., Zhang C., Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf. B: Biointerfaces 2011, 85:262-269.
217. Negi L.M., Jaggi M., Joshi V., Ronodip K., Talegaonkar S. Hyaluronic acid decorated lipid nanocarrier for MDR modulation and CD-44 targeting in colon adenocarcinoma. Int. J. Biol. Macromol. 2015, 72:569-574.
218. Negi L.M., Talegaonkar S., Jaggi M., Verma A.K., Verma R., Dobhal S., Kumar V. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation. Colloids Surf. B: Biointerfaces 2014, 123:600-609.
219. Negi L.M., Talegaonkar S., Jaggi M., Verma A.K., Verma R., Dobhal S., Kumar V. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies. Colloids Surf. B: Biointerfaces 2014, 123:610-615.
220. Qu C.Y., Zhou M., Chen Y.W., Chen M.M., Shen F., Xu L.M. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy. Int. J. Nanomedicine 2015, 10:3911-3920.
221. Yang X.Y., Li Y.X., Li M., Zhang L., Feng L.X., Zhang N. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett. 2013, 334:338-345.
222. Rivkin I., Cohen K., Koffler J., Melikhov D., Peer D., Margalit R. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials 2010, 31:7106-7114.
223. Bachar G., Cohen K., Hod R., Feinmesser R., Mizrachi A., Shpitzer T., Katz O., Peer D. Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. Biomaterials 2011, 32:4840-4848.
224. Peer D. A daunting task: manipulating leukocyte function with RNAi. Immunol. Rev. 2013, 253:185-197.
225. Cohen K., Emmanuel R., Kisin-Finfer E., Shabat D., Peer D. Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. ACS Nano 2014, 8:2183-2195.
226. Mizrahy S., Goldsmith M., Leviatan-Ben-Arye S., Kisin-Finfer E., Redy O., Srinivasan S., Shabat D., Godin B., Peer D. Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. Nanoscale 2014, 6:3742-3752.
227. Kabanov A.V., Vinogradov S.V. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew. Chem. Int. Ed. Engl. 2009, 48:5418-5429.
228. Wen Y., Oh J.K. Recent strategies to develop polysaccharide-based nanomaterials for biomedical applications. Macromol. Rapid Commun. 2014, 35:1819-1832.
229. Jain A., Jain S.K. In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur. J. Pharm. Sci. 2008, 35:404-416.
230. Jain A., Jain S.K., Ganesh N., Barve J., Beg A.M. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomed. Nanotechnol. Biol. Med. 2010, 6:179-190.
231. Deng X., Cao M., Zhang J., Hu K., Yin Z., Zhou Z., Xiao X., Yang Y., Sheng W., Wu Y., Zeng Y. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 2014, 35:4333-4344.
232. Kim E., Yang J., Kim H.O., An Y., Lim E.K., Lee G., Kwon T., Cheong J.H., Suh J.S., Huh Y.M., Haam S. Hyaluronic acid receptor-targetable imidazolized nanovectors for induction of gastric cancer cell death by RNA interference. Biomaterials 2013, 34:4327-4338.
233. Yang X., Iyer A.K., Singh A., Milane L., Choy E., Hornicek F.J., Amiji M.M., Duan Z. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer. Pharm. Res. 2015, 32:2097-2109.
234. Yang X., Iyer A.K., Singh A., Choy E., Hornicek F.J., Amiji M.M., Duan Z. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci. Rep. 2015, 5:8509.
235. Zhang W., Cheng Q., Guo S., Lin D., Huang P., Liu J., Wei T., Deng L., Liang Z., Liang X.J., Dong A. Gene transfection efficacy and biocompatibility of polycation/DNA complexes coated with enzyme degradable PEGylated hyaluronic acid. Biomaterials 2013, 34:6495-6503.
236. Mo R., Jiang T., Disanto R., Tai W., Gu Z. ATP-triggered anticancer drug delivery. Nat. Commun. 2014, 5.
237. Al-Ghananeem A.M., Malkawi A.H., Muammer Y.M., Balko J.M., Black E.P., Mourad W., Romond E. Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations. AAPS PharmSciTech 2009, 10:410-417.
238. Yang C., Wang X., Yao X., Zhang Y., Wu W., Jiang X. Hyaluronic acid nanogels with enzyme-sensitive cross-linking group for drug delivery. J. Control. Release 2015, 205:206-217.
239. Park W., Kim K.S., Bae B.C., Kim Y.H., Na K. Cancer cell specific targeting of nanogels from acetylated hyaluronic acid with low molecular weight. Eur. J. Pharm. Sci. 2010, 40:367-375.
240. Wei X., Senanayake T.H., Bohling A., Vinogradov S.V. Targeted nanogel conjugate for improved stability and cellular permeability of curcumin: synthesis, pharmacokinetics, and tumor growth inhibition. Mol. Pharm. 2014, 11:3112-3122.
241. Maier-Hauff K., Ulrich F., Nestler D., Niehoff H., Wust P., Thiesen B., Orawa H., Budach V., Jordan A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 2011, 103:317-324.
242. Paciotti G.F., Tamarkin L., Zhao J., Cao S., Cao S., Kingston D.G.I. Abstract 3695: CYT-20000: Targeted and temporal delivery of a VDA and chemotherapy by a single gold nanodrug. Cancer Res. 2010, 70:3695.
243. Pellegrino T., Manna L., Kudera S., Liedl T., Koktysh D., Rogach A.L., Keller S., Rädler J., Natile G., Parak W.J. Hydrophobic nanocrystals coated with an amphiphilic polymer shell: A general route to water soluble nanocrystals. Nano Lett. 2004, 4:703-707.
244. Kim J., Kim K.S., Jiang G., Kang H., Kim S., Kim B.-S., Park M.H., Hahn S.K. In vivo real-time bioimaging of hyaluronic acid derivatives using quantum dots. Biopolymers 2008, 89:1144-1153.
245. Kim W., Hur S.-J., Park S.W., Hong J.E., Choi E.J., Goh S.K., Yoon S.K. Hahn, Bioimaging for targeted delivery of hyaluronic Acid derivatives to the livers in cirrhotic mice using quantum dots. ACS Nano 2010, 4:3005-3014.
246. Wang H., Sun H., Wei H., Xi P., Nie S., Ren Q. Biocompatible hyaluronic acid polymer-coated quantum dots for CD44+ cancer cell-targeted imaging. J. Nanoparticle Res. 2014, 16.
247. Xu H., He J., Zhang Y., Fan L., Zhao Y., Xu T., Nie Z., Li X., Huang Z., Lu B., Xu P. Synthesis and in vitro evaluation of a hyaluronic acid-quantum dots-melphalan conjugate. Carbohydr. Polym. 2015, 121:132-139.
248. Muddineti O.S., Ghosh B., Biswas S. Current trends in using polymer coated gold nanoparticles for cancer therapy. Int. J. Pharm. 2015, 484:252-267.
249. Lee H., Lee K., Kim I.K., Park T.G. Synthesis, characterization, and in vivo diagnostic applications of hyaluronic acid immobilized gold nanoprobes. Biomaterials 2008, 29:4709-4718.
250. Kang S.H., Nafiujjaman M., Nurunnabi M., Li L., Khan H.A., Cho K.J., Huh K.M., Lee Y.-k. Hybrid photoactive nanomaterial composed of gold nanoparticles, pheophorbide-A and hyaluronic acid as a targeted bimodal phototherapy. Macromol. Res. 2015, 23:474-484.
251. El-Dakdouki M.H., Zhu D.C., El-Boubbou K., Kamat M., Chen J., Li W., Huang X. Development of Multifunctional Hyaluronan-Coated Nanoparticles for Imaging and Drug Delivery to Cancer Cells. Biomacromolecules 2012, 13:1144-1151.
252. Li J., He Y., Sun W., Luo Y., Cai H., Pan Y., Shen M., Xia J., Shi X. Hyaluronic acid-modified hydrothermally synthesized iron oxide nanoparticles for targeted tumor MR imaging. Biomaterials 2014, 35:3666-3677.
253. Thomas R.G., Moon M.J., Lee H., Sasikala A.R.K., Kim C.S., Park I.K., Jeong Y.Y. Hyaluronic acid conjugated superparamagnetic iron oxide nanoparticle for cancer diagnosis and hyperthermia therapy. Carbohydr. Polym. 2015, 131:439-446.
254. Chen D., Dougherty C.A., Zhu K., Hong H. Theranostic applications of carbon nanomaterials in cancer: Focus on imaging and cargo delivery. J. Control. Release 2015, 210:230-245.
255. Bartelmess J., Quinn S.J., Giordani S. Carbon nanomaterials: Multi-functional agents for biomedical fluorescence and Raman imaging. Chem. Soc. Rev. 2015, 44:4672-4698.
256. Yang X., Ebrahimi A., Li J., Cui Q. Fullerene-biomolecule conjugates and their biomedicinal applications. Int. J. Nanomedicine 2014, 9:77-92.
257. Kwag D.S., Park K., Oh K.T., Lee E.S. Hyaluronated fullerenes with photoluminescent and antitumoral activity. Chem. Commun. 2013, 49:282-284.
258. Kim S., Park J., Youn Y.S., Oh K.T., Bae J.H., Lee E.S. Hoechst 33258-conjugated hyaluronated fullerene for efficient photodynamic tumor therapy and necrotic tumor targeting. J. Bioact. Compat. Polym. 2015, 30:275-288.
259. Ali-Boucetta H., Kostarelos K. Carbon nanotubes in medicine & biology - Therapy and diagnostics. Adv. Drug Deliv. Rev. 2013, 65:1897-1898.
260. Singh R., Torti S.V. Carbon nanotubes in hyperthermia therapy. Adv. Drug Deliv. Rev. 2013, 65:2045-2060.
261. Wong B.S., Yoong S.L., Jagusiak A., Panczyk T., Ho H.K., Ang W.H., Pastorin G. Carbon nanotubes for delivery of small molecule drugs. Adv. Drug Deliv. Rev. 2013, 65:1964-2015.
262. Marega R., Bergamin M., Aroulmoji V., Dinon F., Prato M., Murano E. Hyaluronan-Carbon Nanotube Derivatives: Synthesis, Conjugation with Model Drugs, and DOSY NMR Characterization. Eur. J. Org. Chem. 2011, 2011:5617-5625. (S5617/5611-S5617/5610).
263. Datir S.R., Das M., Singh R.P., Jain S. Hyaluronate Tethered, "Smart" Multiwalled Carbon Nanotubes for Tumor-Targeted Delivery of Doxorubicin. Bioconjug. Chem. 2012, 23:2201-2213.
264. Shi J., Ma R., Wang L., Zhang J., Liu R., Li L., Liu Y., Hou L., Yu X., Gao J., Zhang Z. The application of hyaluronic acid-derivatized carbon nanotubes in hematoporphyrin monomethyl ether-based photodynamic therapy for in vivo and in vitro cancer treatment. Int. J. Nanomedicine 2013, 8:2361-2373.
265. Mo Y., Wang H., Liu J., Lan Y., Guo R., Zhang Y., Xue W., Zhang Y. Controlled release and targeted delivery to cancer cells of doxorubicin from polysaccharide-functionalised single-walled carbon nanotubes. J. Mater. Chem. B 2015, 3:1846-1855.
266. Yao H.J., Zhang Y.G., Sun L., Liu Y. The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials 2014, 35:9208-9223.
267. Cao X., Tao L., Wen S., Hou W., Shi X. Hyaluronic acid-modified multiwalled carbon nanotubes for targeted delivery of doxorubicin into cancer cells. Carbohydr. Res. 2015, 405:70-77.
268. Swierczewska M., Choi K.Y., Mertz E.L., Huang X., Zhang F., Zhu L., Yoon H.Y., Park J.H., Bhirde A., Lee S., Chen X. A Facile, One-Step Nanocarbon Functionalization for Biomedical Applications. Nano Lett. 2012, 12:3613-3620.
269. Dvash R., Khatchatouriants A., Solmesky L.J., Wibroe P.P., Weil M., Moghimi S.M., Peer D. Structural profiling and biological performance of phospholipid-hyaluronan functionalized single-walled carbon nanotubes. J. Control. Release 2013, 170:295-305.
270. Bhirde A.A., Chikkaveeraiah B.V., Srivatsan A., Niu G., Jin A.J., Kapoor A., Wang Z., Patel S., Patel V., Gorbach A.M., Leapman R.D., Gutkind J.S., Hight Walker A.R., Chen X. Targeted therapeutic nanotubes influence the viscoelasticity of cancer cells to overcome drug resistance. ACS Nano 2014, 8:4177-4189.
271. Zheng X.T., Ananthanarayanan A., Luo K.Q., Chen P. Glowing graphene quantum dots and carbon dots: Properties, syntheses, and biological applications. Small 2015, 11:1620-1636.
272. Li F., Park S.-J., Ling D., Park W., Han J.Y., Na K., Char K. Hyaluronic acid-conjugated graphene oxide/photosensitizer nanohybrids for cancer targeted photodynamic therapy. J. Mater. Chem. B 2013, 1:1678-1686.
273. Hou L., Feng Q., Wang Y., Zhang H., Jiang G., Yang X., Ren J., Zhu X., Shi Y., Zhang Z. Multifunctional nanosheets based on hyaluronic acid modified graphene oxide for tumor-targeting chemophotothermal therapy. J. Nanoparticle Res. 2015, 17.
274. Wu H., Shi H., Wang Y., Jia X., Tang C., Zhang J., Yang S. Hyaluronic acid conjugated graphene oxide for targeted drug delivery. Carbon 2014, 69:379-389.
275. Byun E., Lee H. Enhanced loading efficiency and sustained release of doxorubicin from hyaluronic acid/graphene oxide composite hydrogels by a mussel-inspired catecholamine. J. Nanosci. Nanotechnol. 2014, 14:7395-7401.
276. Al Nahain A., Lee J.-E., In I., Lee H., Lee K.D., Jeong J.H., Park S.Y. Target Delivery and Cell Imaging Using Hyaluronic Acid-Functionalized Graphene Quantum Dots. Mol. Pharm. 2013, 10:3736-3744.
277. Baeza A., Colilla M., Vallet-Regí M. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery. Expert Opin. Drug Deliv. 2015, 12:319-337.
278. Chen Z., Li Z., Lin Y., Yin M., Ren J., Qu X. Bioresponsive hyaluronic acid-capped mesoporous silica nanoparticles for targeted drug delivery. Chem. Eur. J. 2013, 19:1778-1783.
279. Zhao Q., Liu J., Zhu W., Sun C., Di D., Zhang Y., Wang P., Wang Z., Wang S. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells. Acta Biomater. 2015, 23:147-156.
280. Wang X., Chen H., Zhang K., Ma M., Li F., Zeng D., Zheng S., Chen Y., Jiang L., Xu H., Shi J. An intelligent nanotheranostic agent for targeting, redox-responsive ultrasound imaging, and imaging-guided high-intensity focused ultrasound synergistic therapy. Small 2014, 10:1403-1411.
281. El-Dakdouki M.H., Puré E., Huang X. Development of drug loaded nanoparticles for tumor targeting. Part 1: Synthesis, characterization, and biological evaluation in 2D cell cultures. Nanoscale 2013, 5:3895-3903.
282. El-Dakdouki M.H., Puré E., Huang X. Development of drug loaded nanoparticles for tumor targeting. Part 2: Enhancement of tumor penetration through receptor mediated transcytosis in 3D tumor models. Nanoscale 2013, 5:3904-3911.
283. Huang L., Ao L., Wang W., Hu D., Sheng Z., Su W. Multifunctional magnetic silica nanotubes for MR imaging and targeted drug delivery. Chem. Commun. 2015, 51:3923-3926.
284. Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. J. Anat. 1996, 189(Pt 3):503-505.
285. Laeschke K. Biocompatibility of microparticles into soft tissue fillers. Semin. Cutan. Med. Surg. 2004, 23:214-217.
286. Aly M.N. Intra-articular drug delivery: a fast growing approach. Recent Pat. Drug Deliv. Formul. 2008, 2:231-237.
287. Li S.D., Howell S.B. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol. Pharm. 2010, 7:280-290.
288. Genc L., Buyuktiryaki S. Preparation and characterization of methotrexate-loaded microcapsules. Pharm. Dev. Technol. 2014, 19:42-47.
289. Harada S., Ehara S., Ishii K., Yamazaki H., Matsuyama S., Sato T., Oikawa S., Kamiya T., Arakawa K., Yokota W., Sera K., Ito J. Targeted delivery of chemotherapeutic agents using improved radiosensitive liquid core microcapsules and assessment of their antitumor effect. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75:455-462.
290. Needham C.J., Shah S.R., Mountziaris P.M., Kasper F.K., Mikos A.G. Modulation of polyplex release from biodegradable microparticles through poly(ethylenimine) modification and varying loading concentration. Pharm. Res. 2014, 31:77-85.
291. DeMerlis C.C., Schoneker D.R. Review of the oral toxicity of polyvinyl alcohol (PVA). Food Chem. Toxicol. 2003, 41:319-326.
292. Cerroni B., Chiessi E., Margheritelli S., Oddo L., Paradossi G. Polymer shelled microparticles for a targeted doxorubicin delivery in cancer therapy. Biomacromolecules 2011, 12:593-601.
293. Nimmo C.M., Shoichet M.S. Regenerative biomaterials that "click": simple, aqueous-based protocols for hydrogel synthesis, surface immobilization, and 3D patterning. Bioconjug. Chem. 2011, 22:2199-2209.
294. Kupal S.G., Cerroni B., Ghugare S.V., Chiessi E., Paradossi G. Biointerface properties of core-shell poly(vinyl alcohol)-hyaluronic acid microgels based on chemoselective chemistry. Biomacromolecules 2012, 13:3592-3601.
295. Anderegg U., Simon J.C., Averbeck M. More than just a filler - the role of hyaluronan for skin homeostasis. Exp. Dermatol. 2014, 23:295-303.
296. Price R.D., Myers S., Leigh I.M., Navsaria H.A. The role of hyaluronic acid in wound healing: Assessment of clinical evidence. Am. J. Clin. Dermatol. 2005, 6:393-402.
297. Tamer T.M. Hyaluronan and synovial joint: Function, distribution and healing. Interdiscip. Toxicol. 2013, 6:111-125.
298. Prestwich G.D. Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine. J. Control. Release 2011, 155:193-199.
299. Burdick J.A., Prestwich G.D. Hyaluronic acid hydrogels for biomedical applications. Adv. Mater. 2011, 23:H41-H56.
300. Emoto S., Yamaguchi H., Kamei T., Ishigami H., Suhara T., Suzuki Y., Ito T., Kitayama J., Watanabe T. Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer. Surg. Today 2014, 44:919-926.
301. Chen J.P., Leu Y.L., Fang C.L., Chen C.H., Fang J.Y. Thermosensitive hydrogels composed of hyaluronic acid and gelatin as carriers for the intravesical administration of cisplatin. J. Pharm. Sci. 2011, 100:655-666.
302. Chen Y.Y., Wu H.C., Sun J.S., Dong G.C., Wang T.W. Injectable and thermoresponsive self-assembled nanocomposite hydrogel for long-term anticancer drug delivery. Langmuir 2013, 29:3721-3729.
303. Jhan H.J., Liu J.J., Chen Y.C., Liu D.Z., Sheu M.T., Ho H.O. Novel injectable thermosensitive hydrogels for delivering hyaluronic acid-doxorubicin nanocomplexes to locally treat tumors. Nanomedicine 2015, 10:1263-1274.
304. Bajaj G., Kim M.R., Mohammed S.I., Yeo Y. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. J. Control. Release 2012, 158:386-392.
305. Lee G.C., Chae S.Y., Park J.H., Kim Y.J. Sustained release system of PEG-TRAIL/hyaluronic acid nanocomposite hydrogel for treating and preventing cancer and autoimmune disease 2009, (KR2009118629A).
306. Byeon H.J., Choi S.H., Choi J.S., Kim I., Shin B.S., Lee E.S., Park E.S., Lee K.C., Youn Y.S. Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer. Acta Biomater. 2014, 10:142-150.
307. Xu K., Lee F., Gao S.J., Chung J.E., Yano H., Kurisawa M. Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy. J. Control. Release 2013, 166:203-210.
308. Montanari E., Capece S., Di Meo C., Meringolo M., Coviello T., Agostinelli E., Matricardi P. Hyaluronic acid nanohydrogels as a useful tool for BSAO immobilization in the treatment of melanoma cancer cells. Macromol. Biosci. 2013, 13:1185-1194.
309. Varghese O.P., Sun W., Hilborn J., Ossipov D.A. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach. J. Am. Chem. Soc. 2009, 131:8781-8783.
310. Lei Y., Huang S., Sharif-Kashani P., Chen Y., Kavehpour P., Segura T. Incorporation of active DNA/cationic polymer polyplexes into hydrogel scaffolds. Biomaterials 2010, 31:9106-9116.
311. Lei Y., Rahim M., Ng Q., Segura T. Hyaluronic acid and fibrin hydrogels with concentrated DNA/PEI polyplexes for local gene delivery. J. Control. Release 2011, 153:255-261.
312. Brown T.J. A composition and method for the enhancement of the efficacy of drugs 2000, (WO0041730A1).
313. Brown T.J. The development of hyaluronan as a drug transporter and excipient for chemotherapeutic drugs. Curr. Pharm. Biotechnol. 2008, 9:253-260.
314. Gibbs P., Clingan P.R., Ganju V., Strickland A.H., Wong S.S., Tebbutt N.C., Underhill C.R., Fox R.M., Clavant S.P., Leung J., Pho M., Brown T.J. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: A randomized phase II trial. Cancer Chemother. Pharmacol. 2011, 67:153-163.
315. HA-Irinotecan in patients with metastatic colorectal cancer 2015, (Alchemia web site).
316. Riechelmann H., Sauter A., Golze W., Hanft G., Schroen C., Hoermann K., Erhardt T., Gronau S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 2008, 44:823-829.
317. Choi K.Y., Min K.H., Yoon H.Y., Kim K., Park J.H., Kwon I.C., Choi K., Jeong S.Y. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 2011, 32:1880-1889.
318. Wong A.D., Ye M., Ulmschneider M.B., Searson P.C. Quantitative analysis of the Enhanced Permeation and Retention (EPR) effect. PLoS One 2015, 10.
319. Charrois G.J.R., Allen T.M. Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity. J. Pharmacol. Exp. Ther. 2003, 306:1058-1067.